期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma:a prospective non.randomized study 被引量:111
1
作者 Min-Ke He Yong Le +5 位作者 qi-jiong li Zi-Shan Yu Shao-Hua li Wei Wei Rong-Ping Guo Ming Shi 《Chinese Journal of Cancer》 SCIE CAS CSCD 2017年第12期704-711,共8页
Background: Transarterial chemoembolization(TACE) is recommended as the standard care for unresectable hepatocellular carcinoma(HCC) at Barcelona Clinic Liver Cancer(BCLC) stage A-B. However, the efficacy of TACE on l... Background: Transarterial chemoembolization(TACE) is recommended as the standard care for unresectable hepatocellular carcinoma(HCC) at Barcelona Clinic Liver Cancer(BCLC) stage A-B. However, the efficacy of TACE on large(> 10 cm) stage A-B HCC is far from satisfactory, and it is proposed that hepatic artery infusion chemotherapy(HAIC)might be a better first-line treatment of this disease. Hence, we compared the safety and efficacy of HAIC with the modified FOLFOX(mFOLFOX) regimen and those ofTACE in patients with massive unresectable HCC.Methods: A prospective, non-randomized, phase II study was conducted on patients with massive unresectable HCC. The protocol involved HAIC with the mFOLFOX regimen(oxaliplatin, 85 mg/m^2 intra-arterial infusion; leucovorin,400 mg/m^2 intra-arterial infusion; and fluorouracil, 400 mg/m2 bolus infusion and 2400 mg/m^2 continuous infusion)every 3 weeks and TACE with 50 mg of epirubicin, 50 mg of lobaplatin, 6 mg of mitomycin, and lipiodol and polyvinyl alcohol particles. The tumor responses, time-to-progression(TTP), and safety were assessed.Results: A total of 79 patients were recruited for this study: 38 in the HAIC group and 41 in the TACE group. The HAIC group exhibited higher partial response and disease control rates than did the TACE group(52.6% vs. 9.8%, P < 0.001;83.8% vs. 52.5%, P = 0.004). The median TTPs for the HAIC and TACE groups were 5.87 and 3.6 months(hazard radio[HR] = 2.35,95% confidence interval [CI] = 1.16-4.76, P = 0.015). More patients in the HAIC group than in the TACE group underwent resection(10 vs. 3,P = 0.033). The proportions of grade 3-4 adverse events(AE) and serious adverse events(SAE) were lower in the HAIC group than in the TACE group(grade 3-4 AEs: 13 vs. 27, P = 0.007;SAEs: 6 vs. 15,p = 0.044). More patients in the TACE group than in the HAIC group had the study treatment terminated early due to intolerable treatment-related adverse events or the withdrawal of consent(10 vs. 2,P = 0.026).Conclusions: HAIC with mFOLFOX yielded significantly better treatment responses and less serious toxicity than did TACE. HAIC might represent a feasible and promising first-line treatment for patients with massive unresectable HCC. 展开更多
关键词 HEPATOCELLULAR carcinoma Hepatic ARTERY INFUSION chemotherapy Transarterial CHEMOEMBOLIZATION mFOLFOX
下载PDF
使用mFOLFOX进行肝动脉灌注化疗与肝动脉化疗栓塞术治疗不可切除的巨块型肝细胞癌:一项前瞻性非随机研究 被引量:6
2
作者 Min-Ke He Yong Le +5 位作者 qi-jiong li Zi-Shan Yu Shao-Hua li Wei Wei Rong-Ping Guo Ming Shi 《癌症》 SCIE CAS CSCD 2018年第6期251-259,共9页
背景与目的肝动脉化疗栓塞术(transarterial chemoembolization,TACE)被推荐为巴塞罗那临床肝癌(Barcelona Clinic Liver Cancer,BCLC)A–B期的不可切除肝细胞癌(hepatocellular carcinoma,HCC)的标准治疗方法。然而,TACE对巨大(≥10 c... 背景与目的肝动脉化疗栓塞术(transarterial chemoembolization,TACE)被推荐为巴塞罗那临床肝癌(Barcelona Clinic Liver Cancer,BCLC)A–B期的不可切除肝细胞癌(hepatocellular carcinoma,HCC)的标准治疗方法。然而,TACE对巨大(≥10 cm)A–B期HCC的疗效远不能令人满意,肝动脉灌注化疗(hepatic artery infusion chemotherapy,HAIC)被认为可能是该疾病更好的一线治疗方法。因此,我们比较了使用改良的FOLFOX方案(modified FOLFOX,mFOLFOX)进行HAIC与TACE治疗不可切除的巨块型HCC的安全性和有效性。方法一项前瞻性非随机II期研究在患有不可切除的巨块型HCC患者中开展。治疗方法为使用mFOLFOX方案每3周进行一次HAIC(奥沙利铂,85 mg/m^2动脉灌注;甲酰四氢叶酸,400 mg/m^2动脉灌注;氟尿嘧啶,400 mg/m^2静脉推注和2400 mg/m^2持续静脉滴注),使用50 mg表柔比星、50 mg洛铂、6 mg丝裂霉素和碘油聚乙烯醇颗粒进行TACE。评估了肿瘤反应、肿瘤进展时间(time-to-progression,TTP)和安全性。结果本研究共招募了79例患者:HAIC组38例,TACE组41例。HAIC组的部分缓解率和疾病控制率均高于TACE组(52.6%vs.9.8%,P<0.001;83.8%vs.52.5%,P=0.004)。HAIC和TACE组的中位TTP分别为5.87和3.6个月[风险比(hazard ratio,HR)=2.35,95%置信区间(confidence interval,CI)=1.16–4.76,P=0.015)]。HAIC组比TACE组有更多的患者接受了手术切除(10 vs.3,P=0.033)。HAIC组中3–4级不良事件(adverse events,AE)和严重不良事件(serious adverse events,SAE)发生数均低于TACE组(3–4级AE:13 vs.27,P=0.007;SAE:6 vs.15,P=0.044)。因无法耐受的治疗相关不良事件或撤回知情同意书而导致治疗提前终止的患者在TACE组中多于HAIC组(10 vs.2,P=0.026)。结论与TACE相比,使用mFOLFOX进行HAIC表现出显著优势的治疗反应性和更低的毒性。对于不可切除的巨块型HCC,HAIC可能是一种可行且有前景的一线治疗方法。 展开更多
关键词 肝细胞癌 肝动脉灌注化疗 肝动脉化疗栓塞术 mFOLFOX
下载PDF
A modified radiofrequency ablation approach for treating distant lymph node metastasis in two patients with late-stage cancer
3
作者 Ru-Hai Zou qi-jiong li +3 位作者 Ji-liang Qiu Ya-Di liao Yun-Fei Yuan An-Hua li 《Chinese Journal of Cancer》 SCIE CAS CSCD 2013年第10期567-570,共4页
Patients with late-stage cancer commonly have distant lymph node metastasis;however,poor health often contraindicates surgical treatment.Although the quality of life and overall survival for these patients are low,the... Patients with late-stage cancer commonly have distant lymph node metastasis;however,poor health often contraindicates surgical treatment.Although the quality of life and overall survival for these patients are low,there is neither a consensus nor a guide for treatment.Ablation technique and surrounding tissue damage are two possible reasons for limited study of radiofrequency ablation in patients with superficial distant lymph node metastasis.Here,we report two patients treated successfully with ultrasound-guided radiofrequency ablation for superficial distant lymph node metastasis.In these patients,deionized water was injected to the surrounding tissues of the lymph node to decrease heat injury.Results from these patients suggest that radiofrequency ablation may play an important role in the treatment of patients with distant lymph node metastasis. 展开更多
关键词 手术治疗 射频消融 淋巴结 癌症 晚期 组织损伤 去离子水 患者
下载PDF
预测肝细胞癌腹腔镜肝切除术后复发风险的列线图模型
4
作者 Yang-Xun Pan Jian-Cong Chen +10 位作者 Ai-Ping Fang Xiao-Hui Wang Jin-Bin Chen Jun-Cheng Wang Wei He Yi-Zhen Fu li Xu Min-Shan Chen Yao-Jun Zhang qi-jiong li Zhong-Guo Zhou 《癌症》 SCIE CAS CSCD 2019年第12期551-562,共12页
背景与目的肝细胞癌(hepatocellular carcinoma,HCC)患者手术切除术后5年复发率很高(60%)。腹腔镜肝切除术(laparoscopic hepatectomy,LH)不断发展,但鲜有研究对LH与传统手术方法治疗HCC的疗效进行比较。本研究旨在建立一种预测HCC患者L... 背景与目的肝细胞癌(hepatocellular carcinoma,HCC)患者手术切除术后5年复发率很高(60%)。腹腔镜肝切除术(laparoscopic hepatectomy,LH)不断发展,但鲜有研究对LH与传统手术方法治疗HCC的疗效进行比较。本研究旨在建立一种预测HCC患者LH后复发风险的列线图模型。方法收集432例病理确诊为HCC并首次接受LH治疗且手术切缘>1cm的患者的临床资料。评估了其临床病理特征对无复发生存期(recurrence-free survival,RFS)的影响,在此基础上,使用训练队列(n=324)建立了列线图,并在现有的验证队列(n=108)中进行了内部验证。结果乙型肝炎表面抗原[风险比(hazard ratio,HR),1.838;P=0.044]、肿瘤数目(HR,1.774;P=0.003)、癌栓(HR,2.356;P=0.003)、癌细胞分化程度(HR,0.745;P=0.080)和肿瘤微血管浸润(HR,1.673;P=0.007)是训练队列中RFS的独立预后因素,并用于建立列线图。采用列线图预测RFS的C-index为0.786,高于第8版美国癌症联合会TNM分期系统(C-index,0.698)和巴塞罗那临床肝癌分期系统(C-index,0.632)。校准曲线也证明了列线图预测结果与实际生存一致性较高。受试者工作特征曲线分析表明,与其他系统相比,该列线图对RFS的预测效果更佳,具有更高的阈值概率,这在验证队列中也得到了证实。结论我们建立和验证了可将HCC患者首次接受LH后复发风险量化的列线图,该列线图可应用于临床,辅助医生对患者制订个性化术后监测方案。 展开更多
关键词 肝细胞癌 腹腔镜肝切除术 复发 列线图 美国癌症联合会TNM分期系统 巴塞罗那临床肝癌分期系统 乙型肝炎表面抗原 癌栓 肿瘤浸润
下载PDF
A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomy 被引量:16
5
作者 Yang-Xun Pan Jian-Cong Chen +10 位作者 Ai-Ping Fang Xiao-Hui Wang Jin-Bin Chen Jun-Cheng Wang Wei He Yi-Zhen Fu li Xu Min-Shan Chen Yao-Jun Zhang qi-jiong li Zhong-Guo Zhou 《Cancer Communications》 SCIE 2019年第1期499-509,共11页
Background:Patients with hepatocellular carcinoma(HCC)undergoing surgical resection still have a high 5-year recurrence rate(~60%).With the development of laparoscopic hepatectomy(LH),few studies have compared the eff... Background:Patients with hepatocellular carcinoma(HCC)undergoing surgical resection still have a high 5-year recurrence rate(~60%).With the development of laparoscopic hepatectomy(LH),few studies have compared the efficacy between LH and traditional surgical approach on HCC.The objective of this study was to establish a nomo-gram to evaluate the risk of recurrence in HCC patients who underwent LH.Methods:The clinical data of 432 patients,pathologically diagnosed with HCC,underwent LH as initial treatment and had surgical margin>1 cm were collected.The significance of their clinicopathological features to recurrence-free survival(RFS)was assessed,based on which a nomogram was constructed using a training cohort(n=324)and was internally validated using a temporal validation cohort(n=108).Results:Hepatitis B surface antigen(hazard ratio[HR],1.838;P=0.044),tumor number(HR,1.774;P=0.003),tumor thrombus(HR,2.356;P=0.003),cancer cell differentiation(HR,0.745;P=0.080),and microvascular tumor invasion(HR,1.673;P=0.007)were found to be independent risk factors for RFS in the training cohort,and were used for con-structing the nomogram.The C-index for RFS prediction in the training cohort using the nomogram was 0.786,which was higher than that of the 8th edition of the American Joint Committee on Cancer TNM classification(C-index,0.698)and the Barcelona Clinic Liver Cancer staging system(C-index,0.632).A high consistency between the nomogram prediction and actual observation was also demonstrated by a calibration curve.An improved predictive benefit in RFS and higher threshold probability of the nomogram were determined by receiver operating characteristic curve analysis,which was also confirmed in the validation cohort compared to other systems.Conclusions:We constructed and validated a nomogram able to quantify the risk of recurrence after initial LH for HCC patients,which can be clinically implemented in assisting the planification of individual postoperative surveil-lance protocols. 展开更多
关键词 Hepatocellular carcinoma Laparoscopic hepatectomy RECURRENCE NOMOGRAM American Joint Committee on Cancer TNM classification Barcelona Clinic Liver Cancer staging system Hepatitis B surface antigen Tumor thrombus Tumor invasion
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部